Safety of antipsychotic drugs: Focus on therapeutic and adverse effects

Expert Opinion on Drug Safety

Volumn 13, Issue 8, 2014, Pages 1031-1042

  Werner, Felix Martin ^a,b   Coveñas, Rafael ^b  

^a Höhere Berufsfachschule für Altenpflege und Ergotherapie der Euro Akademie Pößneck   (Germany)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Aripiprazole; Asenapine; Cariprazine; Clinical trial; Clozapine; Lurasidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Side effects; Tolerability; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARIPRAZINE; CLOZAPINE; HALOPERIDOL; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; SEROTONIN 2 ANTAGONIST;

AGRANULOCYTOSIS; AKATHISIA; CONSTIPATION; DISEASES; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; HEART PALPITATION; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INSOMNIA; LIVER INJURY; META ANALYSIS (TOPIC); METABOLIC DISORDER; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOEDUCATION; PSYCHOSOCIAL CARE; RECURRENCE RISK; REMISSION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOPAMINE D2 RECEPTOR ANTAGONISTS; HUMANS; MEDICATION ADHERENCE; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84904473696     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.935761     Document Type: Review

References (46)

1. Klosterkoetter J. Indicated prevention of schizophrenia. Dtsch Arztebl Int 2008;105:532-9
2. Werner FM, Coveñas R. Classical neurotransmitter and neuropeptides involved in schizophrenia: How to choose the appropriate antipsychotic drug?. Curr Drug Ther 2013;8:132-43
3. Vasilyeva I, Biscontri RG, Enns MW, et al. Movement disorders in elderly users of risperidone and first generation antipsychotic agents: A Canadian population-based study. PLoS One 2013;8:e64217
4. Thomas SP, Nandhra HS, Singh SP. Pharmacological treatment of firsteipsode schizophrenia: A review of the literature. Prim Care Companion CNS Disord 2012;14:PCC.11r01198
5. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 2012;18:S1-20
6. Elsworth JD, Groman SM, Jentsch JD, et al. Asenapine effects on cognitive and monamine dysfunction elicited by subchronic phencyclidine administration. Neuropsychopharmacology 2011;62:1442-52
7. Tajima K, Fernández H, López-Ibor JJ, et al. Tratamientos para la esquizofrenia. Revisión crítica sobre la farmacología y mecanismos De acción De los antipsicóticos. Actas Esp Psiquiatr 2009;37:330-42
8. Nasrallah HA, Silva R, Philipps D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47:670-7
9. Caccia S, Invernizzi RW, Nobili A, et al. A new generation of antipsychotics: Pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag 2013;9:319-28
10. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: A 6-month, open-label, extension study. J Clin Psychiatry 2013;74:507-15
11. Novakovic V, Adel T, Peselow E, et al. Long-Acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clin Neuropharmacol 2013;36:59-62
12. Klingberg S, Herrlich J, Wiedemann G, et al. Adverse effects of cognitive behavioural therapy and cognitive remediation in schizophrenia: Results of the treatment of negative symptoms study. J Nerv Ment Dis 2012;200:569-76
13. Venkatesh PR, Kozielska M, Suleiman AA, et al. Pharmacokineticpharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia part I: The use of PANSS total score and clinical utility. Schizophr Res 2013;146:146-52
14. Venkatesh PR, Kozielska M, Suleiman AA, et al. Pharmacokinetic- pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia part II: The use of subscales of the PANSS score. Schizophr Res 2013;146:153-61
15. Citrome L. Oral paliperidone extendedrelease: Chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol 2012;8:873-88
16. Amr M, Lakhan SE, Sanhan S, et al. Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: A randomized clinical trial. Int Arch Med 2013;6:47 6 and 12 weeks
17. Shang DW, Li LJ, Wang XP, et al. Population pharmacokinetic/ pharmacodynamic model for clozapine for characterising the relationship between accumulated exposure and PANSS scores in patients with schizophrenia. Ther Drug Monit 2014;36(3):378-86
18. Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014;1:CD006569
19. Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health 2012;30:153-9
20. Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizoprenia or schizoaffective patients switched from other antipsychotic drugs: A 6-month, open-label, extension study. CNS Spectr 2013;16:1-10
21. Leucht S, Zhao J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol 2014;28:387-94
22. Potkin SG, Phiri P, Szegedi A, et al. Long-Term effects of asenapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis. Schizophr Res 2013;150:442-9
23. Szegedi A, Verweij P, van Duijnhoven W, et al. Meta-Analysis of the efficacy of asenapine for acute schizophrenia: Comparisons with placebo and other antipsychotics. J Clin Psychiatry 2012;73:1533-40
24. Weber J, McCormack PL. Asenapine. CNS Drugs 2009;23:781-92
25. Citrome L. Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol 2013;9:193-206
26. Citrome L. Cariprazine in schizophrenia: Clinical efficacy, tolerability, and place in therapy. Adv Ther 2013;30:114-26
27. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute excacerbation of schizophrenia: A phase II randomized, clinical trial. Schizophr Res 2014;152:450-7
28. Werner FM, Coveñas R. Possible therapeutic options in Parkinson's disease according to a neuronal network. Neurol Rehabil 2012;18:420-1
29. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine or placebo: A 6-month, open-label, extension study. J Clin Psychiatry 2013;74:507-15
30. Stoner SC, Pace HA. Asenapine: A clinical review of a second-generation antipsychotic. Clin Ther 2012;34:1023-40
31. Gopal S, Hough D, Karcher K, et al. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: Analysis of 64 randomized, double-blind trials. J Clin Psychopharmacol 2013;33:157-61
32. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-To-head comparison of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-Analysis. Schizophr Res 2010;123:225-33
33. Bodén R, Edman G, Reutfors J, et al. A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat 2013;9:371-7
34. Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry 2014;75(3):238-45
35. Wang ZM, Xiang YT, An FR, et al. Frequency of hyperprolactinemia and its association with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. Perpect Psychiatric Care 2013;doi: 10.1111/ppc.12050
36. Besnard I, Auclair V, Callery G, et al. Antipsychotic-drug- inducedhyperprolactinemia: Pathophysiology, clinical features and guidance. Encephale 2013;40:86-94
37. Yeon WP, Yooseok K, Yun HL. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health 2012;30:153-9
38. Najim H, Islam N. Checking physical care of people on risperidone long term injectable depot. Psychiatr Danub 2013;25:S171-3
39. Caccia S. Biotransformation of post-clozapine antipsychotics: Pharmacological implications. Clin Pharmacokinet 2000;38:393-414
40. Khan AA, Harvey J, Sengupta S. Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia. Psychopharmacol 2013;3:266-71
41. Ringbäck Weitoft G, Berglund M, Lindstrom EA, et al. Mortality, attempted suicide, rehospitalization and prescription refill for clozapine and other antipsychotics in Sweden-A register-based study. Pharmacoepidemiol Drug Saf 2014;23:290-8
42. Duncan EJ, Woolson SL, Hamer RM. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-Acting injectable. Int Clin Psychopharmacol 2012;27:283-90
43. Crespo-Facorro B, De la Foz VO, Mata I, et al. Treatment of first-episode non-Affective psychosis: A randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology (Berl) 2013;231:357-66
44. Park JI, Cho DH, Hahn SW, et al. The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. Int Clin Psychopharmacol 2014;29:77-85
45. Dold S, Leucht M. Pharmacotherapy of treatment-resistant schizophrenia: A clinical perspective. Evid Based Ment Health 2014;17:32-7
46. Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine?. A nationwide study in Hungary. Schizophr Res 2014;152:246-54